|
|
 |
 |
 |
|
|
|||
|
||||
|
||||
Re: Conservative Surgery for Borderline Ovarian TumorsFrom: art fougner, md (evsono@pipeline.com)Tue Dec 2 15:16:12 1997
At Tue, 2 Dec 1997, Marco A. Pelosi, III, MD wrote: > >A recent case report of unilateral laparoscopic adnexectomy yielded a >borderline mucinous tumor, apparently confined to the ovary, in a young >nullipara; frozen section was benign. > >It raises several "what would you do"s. >
SNIP
> here's an interesting slant on borderline or low malignant potential tumors which may be pertinent here. Int J Gynecol Pathol 1993 Apr;12(2):120-127 The behavior of serous tumors of low malignant potential: are they ever malignant? Kurman RJ, Trimble CL Although the literature describing the clinicopathologic features of serous borderline or low malignant potential (LMP) tumors of the ovary is extensive, the behavior of these neoplasms is not well understood. While some studies indicate a 30 to 40% mortality for advanced stage tumors, it is not clear whether this poor outcome is related to "benign" complications of the disease, such as bowel obstruction from adhesions, or to development of carcinomatosis from malignant transformation. In an effort to determine more clearly the cause of death of patients with serous LMP tumors and to assess the malignant potential of these tumors, defined by progression to invasive serous carcinoma, we reviewed 22 series, totalling 953 patients. Analysis of these studies reveals that for patients with stage I tumors, survival is 99%. For advanced stage disease, survival is 92%. Advanced-stage tumors associated with so-called invasive implants were excluded from this analysis because they were considered invasive serous carcinomas at the time of diagnosis rather than noninvasive LMP tumors. Various causes of death in patients with advanced-stage tumors include complications of the disease, complications of therapy, and, rarely, malignant transformation. Our review of 953 cases disclosed only seven (0.7%) tumors that appeared to have undergone malignant transformation, resulting in death from intraabdominal carcinomatosis. Because the rate of malignant transformation is exceedingly low and because classifying these tumors as malignant often leads to unnecessary treatment, we believe that the term low malignant potential or borderline tumor is not justified. interesting no? definitely controversial but food for thought.
-- art fougner, md SonoScan/Genetic Sciences forest hills, ny evsono@pipeline.com
|
|
Return to
|
Mail a New Message to the Forum: ob-gyn-l@obgyn.net Forum Administrator: geffrey.klein@obgyn.net Report Technical Problems: webmaster@obgyn.net Last Updated: Wed Dec 2 05:22:30 2009 |
The American Medical Association is no longer designating CME hours for AMA Category II CME credit. However, physicians themselves may self designate learning activities as Category II CME credit hours if they feel it is of sufficient educational merit and meets the formal definitions of continuing medical education. OBGYN.net believes these interaction in this forum meets these criteria. For further information see the AMA web site.